<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00809185</url>
  </required_header>
  <id_info>
    <org_study_id>CASE1905</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CCF-8514</secondary_id>
    <secondary_id>CASE1905</secondary_id>
    <nct_id>NCT00809185</nct_id>
  </id_info>
  <brief_title>RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes</brief_title>
  <official_title>A Phase 2 Trial of RAD001(Everolimus) in Low and Intermediate-1 Risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: RAD001(Everolimus) may stop the growth of cancer cells by blocking some of the
      enzymes needed for their growth and by blocking blood flow to the cancer.

      PURPOSE: This phase II trial is studying how well RAD001(everolimus) works in treating
      patients with myelodysplastic syndromes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the clinical activity (improvement in erythroid response and/or improvement in
           other cytopenias, bone marrow morphology/cytogenetics) of RAD001(everolimus) in patients
           with low or intermediate-1 risk myelodysplastic syndromes.

        -  Assess the toxicity of this drug in these patients.

      Secondary

        -  Examine laboratory correlates (S6K1 levels, angiogenesis pre- and post-treatment) and
           determine how these correlates correspond to dosing and clinical activity of
           RAD001(everolimus).

        -  Evaluate the presence of HLA-DR15 and cytotoxic T-cell populations in patients pre- and
           post-treatment and correlate this with response to treatment.

        -  Examine the incidence of the null GSTT-1 phenotype in myelodysplastic syndromes patients
           and correlate this with response to RAD001(everolimus).

      OUTLINE: Patients receive oral RAD001(everolimus) once daily on days 1-21. Courses repeat
      every 28 days in the absence of disease progression or relapse.

      Blood samples are collected periodically during study. Samples are analyzed for S6K1
      activity, effector T cells by flow cytometry, GSTT-1 by PCR, and HLA-DR15 levels.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual
  </why_stopped>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Either a Major or Minor Erythroid Response(Hemoglobin Change From Baseline Measure)</measure>
    <time_frame>2 years of treatment</time_frame>
    <description>Major erythroid response: (1) For patients with a baseline hemoglobin less than 11 g/dL, a major erythroid response is defined as a &gt; 2 g/dL increase in hemoglobin from baseline; or (2) 100% decrease in red blood cell transfusion requirements.
Minor erythroid response: (1) For patients with baseline hemoglobin less than 11 g/dL, a minor erythroid response is defined as an increase in hemoglobin greater than 1 g/dL but less than 2 g/dL from baseline; or (2) &gt; 50% decrease in red blood cell transfusion requirements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose- and Non-dose-limiting Toxicities</measure>
    <time_frame>at end of one cycle (28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Correlates (Cytotoxic T-cell Populations, S6K1 Levels, GSTT-1 Mutations, and Presence or Absence of HLA-DR15)</measure>
    <time_frame>at 2 years of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Marrow Morphology and Cytogenetics Pre- and Post-therapy</measure>
    <time_frame>at 2 years of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>RAD001 (everolimus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RAD001 (everolimus) at 10mg/day with Bone marrow aspirate/biopsy and other laboratory biomarker analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>Patients will receive monotherapy with RAD001(everolimus)for 21 days within the 28 day cycle.</description>
    <arm_group_label>RAD001 (everolimus)</arm_group_label>
    <other_name>RAD001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Laboratory correlates (cytotoxic t cell populations, S6K1 levels, GSTT-1 mutations, and the presence or absence of HLA-DR15) will be assessed to see if any of these correlates correspond to response.</description>
    <arm_group_label>RAD001 (everolimus)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow aspirate/biopsy</intervention_name>
    <description>Bone marrow aspirate and biopsy with cytogenetics should be obtained within 4 weeks prior to starting drug and at week 33. A bone marrow aspirate and biopsy should also be obtained for patients going off study prior to week 33 (including cytogenetics). The percentage of blasts on the aspirate should be used to determine the IPSS score.</description>
    <arm_group_label>RAD001 (everolimus)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Low or intermediate-1 risk myelodysplastic syndromes by International Prognostic
             Scoring System (IPSS) criteria

               -  IPSS score &lt; 1.5

          -  Requiring transfusion of 2 units of red blood cells at least once a month (four weeks
             prior to accrual on study)

          -  High levels of endogenous epoetin alfa (i.e., &gt; 200 mU/mL)

               -  Unlikely to respond to epoetin alfa, or has a documented clinical non-response to
                  epoetin alfa (at a dose of ≥ 40,000 U weekly) or darbepoetin alfa (at a dose &gt;
                  200 mcg every other week) (i.e., &lt; 2 g/dL increase in hemoglobin and no decrease
                  in transfusion requirements after at least 4 weeks of treatment)

          -  No chronic myelomonocytic leukemia

        PATIENT CHARACTERISTICS:

          -  ECOG Performance Status of 0-2

          -  Liver enzymes (AST and ALT) and total bilirubin ≤ 2 times upper limit of normal

          -  Serum creatinine ≤ 2 times upper limits of normal

          -  No clinically significant anemia due to iron, B12, or folate deficiencies; autoimmune
             or hereditary hemolysis; or gastrointestinal bleeding

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other serious or poorly controlled medical condition that could be exacerbated by
             or complicate compliance with study therapy

        PRIOR CONCURRENT THERAPY:

          -  At least 4 weeks since prior treatment (including growth factors)

          -  No chronic use (&gt; 2 weeks) of physiologic doses of a corticosteroid agent (dose
             equivalent to &gt; 10 mg/day of prednisone) within 28 days of the first day of study drug

          -  No concurrent use of another investigational agent

          -  No concurrent therapy with any cytotoxic drugs, steroids, or growth factors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anjali Advani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <results_first_submitted>January 20, 2012</results_first_submitted>
  <results_first_submitted_qc>April 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 4, 2012</results_first_posted>
  <last_update_submitted>September 29, 2015</last_update_submitted>
  <last_update_submitted_qc>September 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from Cleveland Clinic medical hospital from April 2006-March 2009</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>RAD001(Everolimus)</title>
          <description>drug will be administered at 10mg by mouth for 21 days followed by a 7 day rest period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RAD001(Everolimus)</title>
          <description>drug will be administered at 10mg by mouth for 21 days followed by a 7 day rest period</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="60" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Either a Major or Minor Erythroid Response(Hemoglobin Change From Baseline Measure)</title>
        <description>Major erythroid response: (1) For patients with a baseline hemoglobin less than 11 g/dL, a major erythroid response is defined as a &gt; 2 g/dL increase in hemoglobin from baseline; or (2) 100% decrease in red blood cell transfusion requirements.
Minor erythroid response: (1) For patients with baseline hemoglobin less than 11 g/dL, a minor erythroid response is defined as an increase in hemoglobin greater than 1 g/dL but less than 2 g/dL from baseline; or (2) &gt; 50% decrease in red blood cell transfusion requirements.</description>
        <time_frame>2 years of treatment</time_frame>
        <population>All patients enrolled were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RAD001(Everolimus)</title>
            <description>drug will be administered at 10mg by mouth for 21 days followed by a 7 day rest period</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Either a Major or Minor Erythroid Response(Hemoglobin Change From Baseline Measure)</title>
          <description>Major erythroid response: (1) For patients with a baseline hemoglobin less than 11 g/dL, a major erythroid response is defined as a &gt; 2 g/dL increase in hemoglobin from baseline; or (2) 100% decrease in red blood cell transfusion requirements.
Minor erythroid response: (1) For patients with baseline hemoglobin less than 11 g/dL, a minor erythroid response is defined as an increase in hemoglobin greater than 1 g/dL but less than 2 g/dL from baseline; or (2) &gt; 50% decrease in red blood cell transfusion requirements.</description>
          <population>All patients enrolled were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Patients with a Minor Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Patients with a Major Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose- and Non-dose-limiting Toxicities</title>
        <time_frame>at end of one cycle (28 days)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Correlates (Cytotoxic T-cell Populations, S6K1 Levels, GSTT-1 Mutations, and Presence or Absence of HLA-DR15)</title>
        <time_frame>at 2 years of treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Marrow Morphology and Cytogenetics Pre- and Post-therapy</title>
        <time_frame>at 2 years of treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were measure during treatment which ranges from 5-196 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RAD001(Everolimus)</title>
          <description>drug will be administered at 10mg by mouth for 21 days followed by a 7 day rest period</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>fever/infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was stopped early due to slow accrual. 18-33 patients were needed to address objectives, however only 7 patients were enrolled. Insufficient patients responded to the treatment to allow laboratory correlates with response to be analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Anjali Advani</name_or_title>
      <organization>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</organization>
      <phone>216-445-9354</phone>
      <email>advania@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

